Unicycive Therapeutics In... (UNCY)
Unicycive Therapeutics Statistics
Share Statistics
Unicycive Therapeutics has 103.8M shares outstanding. The number of shares has increased by 176% in one year.
| Shares Outstanding | 103.8M |
| Shares Change (YoY) | 176% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 69.36% |
| Shares Floating | 86.07M |
| Failed to Deliver (FTD) Shares | 17.98K |
| FTD / Avg. Volume | 1.84% |
Short Selling Information
The latest short interest is 1.05M, so 1.02% of the outstanding shares have been sold short.
| Short Interest | 1.05M |
| Short % of Shares Out | 1.02% |
| Short % of Float | 1.21% |
| Short Ratio (days to cover) | 0.74 |
Valuation Ratios
The PE ratio is undefined and the forward PE ratio is -1.54. Unicycive Therapeutics's PEG ratio is undefined.
| PE Ratio | undefined |
| Forward PE | -1.54 |
| PS Ratio | 0 |
| Forward PS | 0.1 |
| PB Ratio | 71.59 |
| P/FCF Ratio | undefined |
| PEG Ratio | undefined |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Unicycive Therapeutics Inc..
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.28, with a Debt / Equity ratio of undefined.
| Current Ratio | 1.28 |
| Quick Ratio | 1.28 |
| Debt / Equity | undefined |
| Total Debt / Capitalization | - |
| Cash Flow / Debt | null |
| Interest Coverage | undefined |
Financial Efficiency
Return on equity (ROE) is null% and return on capital (ROIC) is 0%.
| Return on Equity (ROE) | null% |
| Return on Assets (ROA) | null% |
| Return on Capital (ROIC) | 0% |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-2,701,714.29 |
| Employee Count | 14 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -37.82M |
| Effective Tax Rate | 1 |
Stock Price Statistics
The stock price has increased by -60.14% in the last 52 weeks. The beta is 2.25, so Unicycive Therapeutics's price volatility has been higher than the market average.
| Beta | 2.25 |
| 52-Week Price Change | -60.14% |
| 50-Day Moving Average | 0.59 |
| 200-Day Moving Average | 0.52 |
| Relative Strength Index (RSI) | 40.64 |
| Average Volume (20 Days) | 977K |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -32.12M |
| Net Income | -37.82M |
| EBITDA | -32.12M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -0.06 |
Balance Sheet
The company has 26.14M in cash and 681K in debt, giving a net cash position of 25.46M.
| Cash & Cash Equivalents | 26.14M |
| Total Debt | 681K |
| Net Cash | 25.46M |
| Retained Earnings | -101.27M |
| Total Assets | 38.57M |
| Working Capital | 27.28M |
Cash Flow
In the last 12 months, operating cash flow was -28.57M and capital expenditures -72K, giving a free cash flow of -28.65M.
| Operating Cash Flow | -28.57M |
| Capital Expenditures | -72K |
| Free Cash Flow | -28.65M |
| FCF Per Share | -0.04 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
UNCY does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -10.91% |
| FCF Yield | -50.59% |
Analyst Forecast
The average price target for UNCY is $7.5, which is 1263.6% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $7.5 |
| Price Target Difference | 1263.6% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
Scores
| Altman Z-Score | -1.84 |
| Piotroski F-Score | 2 |